

# Contents

|  |      |
|--|------|
| Acknowledgments .....  | viii |
| Foreword .....   | ix   |
| Chapter 1: Introduction to Regulatory Strategy .....   | 1    |
| By Darin S. Oppenheimer, Jessica L. Hale, Suraj Ramachandran and George A. Cusatis                         |      |
| Chapter 2: The Regulatory Team.....  | 9    |
| By Naseem Kabir, Susan Capps and Grace Jiang   |      |
| Chapter 3: Regulatory Intelligence Step 1: Information Collection—A Compilation of Website Addresses ..... | 23   |
| By William K. Sietsema, PhD  |      |
| Chapter 4: The Elements of Global Regulatory Strategy—the Basics.....                                      | 31   |
| By Neal E. Storm   |      |
| Chapter 5: Assembling and Utilizing Target Product Profiles.....   | 45   |
| By Anastassios Retzios, PhD  |      |
| Chapter 6: Preclinical Safety Guidelines Supporting International Drug Registration .....                  | 57   |
| By John C. Kapeghian, PhD, DABT  |      |
| Chapter 7: CMC Regulatory Strategy .....   | 79   |
| By Stephen Antonelli and Michael Craig   |      |
| Chapter 8: Strategies for Clinical Development Planning.....   | 89   |
| By William Sietsema, PhD and Eric Brass, MD, PhD   |      |
| Chapter 9: Clinical Trial Application Planning.....  | 99   |
| By Sharry Arora  |      |
| Chapter 10: Global Orphan Drug Regulations .....   | 107  |
| By Jocelyn Jennings, MS, RAC   |      |
| Chapter 11: Pediatric Strategies.....  | 117  |
| By Klaus Rose, MD, MS  |      |
| Chapter 12: So Your Drug has a Friend? Companion Diagnostic Codevelopment Strategies.....                  | 133  |
| By Catherine Lofton-Day, Dave Kern and Mya Thomae  |      |
| Chapter 13: Interacting With Regulators .....  | 145  |
| By Eric Brass, MD, PhD and William Sietsema, PhD   |      |
| Chapter 14: Regulatory Pathways.....   | 155  |
| By Pallavi Trivedi, MPH, RAC   |      |
| Chapter 15: Global Regulatory Strategy.....  | 187  |
| By Chris Walker and Tina Soulis  |      |
| Chapter 16: Preparing for an FDA Advisory Committee: High Risk, High Reward.....                           | 205  |
| By Michael J. Vivion   |      |
| Chapter 17: Considerations for Healthcare Products' Lifecycle Management .....                             | 221  |
| By Timothy Pang  |      |
| Chapter 18: Medical Writing Strategies: Aligning Regulatory Documents with Strategic Goals.....            | 235  |
| By Kathy Wekselman   |      |
| Index .....  | 243  |

## Case Studies

|  |     |
|--|-----|
| Case Study 8-1. Teduglutide and the Selection of a Clinically Meaningful Endpoint..... | 94  |
| Case Study 8-2. Adverse Events of Special Interest.....                                | 95  |
| Case Study 8-3. Excluding Unacceptable Risk.....                                       | 96  |
| Case Study 13-1. Vascepa for the Treatment of Hypertriglyceridemia.....                | 151 |

## Figures

|  |     |
|--|-----|
| Figure 5-1. Target Product Profile (TPP) Planning Process.....   | 45  |
| Figure 5-2. Target Product Profile.....  | 48  |
| Figure 8-1. Clinical Development Program Reverse-Engineering Principle.....                              | 90  |
| Figure 8-2. Sample Timeline With one Option for Displaying High-Level Information on Program Timing..... | 92  |
| Figure 10-1. Sponsor's Guide to an Orphan Designation.....   | 109 |
| Figure 14-1. EMA Centralised Procedure Flowchart With Major Milestones.....                              | 163 |
| Figure 14-2. Flow Chart of Drug and Device Review in Japan.....  | 167 |
| Figure 14-3 Japan's New Approval System for Commercialization of Cellular Therapy Products.....          | 169 |
| Figure 14-4. Standard Registration Process with TGA.....   | 173 |
| Figure 14-5. TGA Priority Registration Process Diagram.....  | 175 |
| Figure 14-6. TGA Provisional Registration Process Diagram.....   | 177 |
| Figure 14-7. TGA Regulation of Biologicals.....  | 179 |
| Figure 15-1. Multidisciplinary Product Development.....  | 188 |
| Figure 15-2. Key Interactions Between Marketing and Regulatory.....                                      | 190 |
| Figure 15-3. Clinical Development Strategy in Asia.....  | 194 |
| Figure 15-4. The CTD Triangle.....   | 195 |
| Figure 15-5. Global Technology System for Safety Monitoring.....   | 199 |
| Figure 16-1. Typical Advisory Committee Meeting Seating Arrangement.....                                 | 206 |

## Tables

|   |    |
|---|----|
| Table 3-1. Sources of Regulatory Intelligence.....  | 23 |
| Table 3-2. Websites for Healthcare Product Regulations by Region.....                                 | 24 |
| Table 3-3. Regulatory Intelligence Databases.....   | 26 |
| Table 3-4. Professional Associations for Regulatory Professionals.....                                | 26 |
| Table 3-5. Clinical Trial Databases.....  | 27 |
| Table 3-6. Examples of Web Pages for Subscribing to Regulatory Updates.....                           | 28 |
| Table 3-7. Regulatory Agency Twitter Handles.....   | 28 |
| Table 4-1. Key Global Regulatory Plan Elements.....   | 32 |
| Table 4-2. Changes a Global Regulatory Plan Should Anticipate, Mitigate or Manage.....                | 32 |
| Table 4-3. Regulatory Intelligence Tool Examples to Understand the Competitive Product Landscape..... | 39 |
| Table 4-4. Regulatory Journals for Understanding Shifting Regulatory Policy.....                      | 40 |
| Table 4-5. Global Regulatory Plan Components—Sample Table of Contents.....                            | 43 |
| Table 5-1. Introductory/Top Table Presenting Certain Drug Key Elements.....                           | 50 |

|   |     |
|---|-----|
| Table 5-2. TPP Panel for the Clinical use and Efficacy attributes (mainly the primary endpoint) of a Liquid Immunoglobulin G Preparation in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ..... | 51  |
| Table 5-3. TPP Panel Summarizing the Safety Information a Liquid Immunoglobulin G Preparation in the Treatment of Primary Immunodeficiency .....  | 52  |
| Table 5-4. Specific Areas to be Covered by the TPP Asset Characterization Module .....  | 54  |
| Table 6-1. Recommended Duration of Repeat-Dose Toxicity Studies to Support the Conduct of Clinical Trials .....   | 71  |
| Table 7-1. Centralised Procedure Requirements Based on Product Type.....  | 81  |
| Table 7-2. Regulatory Authorities by Country.....   | 81  |
| Table 8-1. Study Outline Document Template.....   | 91  |
| Table 10-1. Countries With Orphan Drug Regulations and Population Prevalence.....   | 110 |
| Table 10-2. Overview of Orphan Drug Designation Incentives .....  | 111 |
| Table 10-3. Global Health Authority Orphan Drug Office.....   | 113 |
| Table 10-4. Orphan Drug Regulations by Country .....  | 114 |
| Table 10-5. Orphan Drug Templates and Submission Tips.....  | 114 |
| Table 13-1. Communication Objectives for Sponsor-Regulator Interactions .....   | 146 |
| Table 13-2. Examples of Open vs. Content-Specific Questions to Regulators.....  | 147 |
| Table 13-3. Summary of Regulatory Agency Meeting Types .....  | 152 |
| Table 14-1. US Pathways and Exclusivity .....   | 156 |
| Table 14-2. FDA Drug and Biologic NDA Application Review Timeframes .....   | 156 |
| Table 14-3. FDA Programs to Expedite Approval of Drug/Biologic Products Intended to Treat Serious Conditions .....  | 160 |
| Table 14-4. EU Application Procedures for Drugs and Biologics .....   | 162 |
| Table 14-5. EU Standard Timelines for Centralised Applications .....  | 162 |
| Table 14-6. EU Standard Mutual Recognition Procedure Timelines .....  | 163 |
| Table 14-7. EU Standard Decentralised Procedure Timelines .....   | 164 |
| Table 14-8. Drug MAA Types in EU.....   | 165 |
| Table 14-9. EU Mechanisms for Accelerated Drug and Biologics Development and Approval.....  | 166 |
| Table 14-10. Japan Drug Filing Fees.....  | 168 |
| Table 14-11. Human Drug (Pharmaceutical and Biological) Submission and Application Review Timeframe and Fees as of April 1, 2019 .....  | 171 |
| Table 14-12. TGA Application and Evaluation Fees in Australian Dollars for Prescription Medicines as of December 2019.....  | 178 |
| Table 14-13. Overview of the TGA Application Process and Timeframes .....   | 180 |
| Table 14-14. TGA Fees in Australia Dollars for Sponsoring Biologicals .....   | 180 |
| Table 15-1. Comparison of Regulatory and HTA Requirements .....   | 191 |
| Table 15-2. Overview of Specific Country Requirements .....   | 197 |
| Table 17-1. CM Considerations by Phase of Product Lifecycle.....  | 223 |
| Table 17-2. Lifecycle Evolution of Oral Antidiabetic Drugs in the US and EU .....   | 227 |
| Table 17-3. Remicade US Indication Expansion in the First Five Years After Launch .....   | 228 |
| Table 18-1. Examples of Structured Regulatory Goals .....   | 238 |
| Table 18-2. Best Practice Examples for Clear Regulatory Writing.....  | 241 |

# Acknowledgments

The Regulatory Affairs Professionals Society thanks those individuals who have shared their experience and expertise with their colleagues by contributing to this book.

## Editors

**Monica Meacham, PhD**  
Associate Director, Regulatory Affairs  
ImmunityBio

**William K. Sietsema, PhD**  
Vice President, Global Regulatory Affairs  
Caladrius Biosciences

## Authors

**Anastassios D. Retzios, PhD**  
President  
Bay Clinical R&D Services, LLC

**Catherine Lofton-Day**  
Formerly at Amgen, Inc.

**Chris Walker, MSc**  
Vice President, European R&D, Head of Regulatory  
Affairs & UK Sites Head  
Amgen, Ltd.

**Darin S. Oppenheimer, DRSc**  
Executive Director Global Regulatory Affairs & Clinical  
Safety Devices and Digital Health  
Merck & Company

**Dave Kern, MBA, RAC**  
Principal and Founder  
K2 Regulatory Consulting

**Eric Brass, MD, PhD**  
Professor Emeritus of Medicine  
David Geffen School of Medicine at UCLA

**George A. Cusatis, RAC**  
Associate Director Global Regulatory Affairs & Clinical  
Safety Devices and Digital Health  
Merck & Company

**Jessica L Hale PharmD**  
Senior Specialist Global Regulatory Affairs & Clinical  
Safety Devices and Digital Health  
Merck & Company

**Jocelyn Jennings, MS, RAC**  
Senior Director, Regulatory Affairs

**John C. Kapeghian, PhD, DAB**  
President  
Preclinical Safety Associates, LL

**Kathryn Wekselman PhD**  
Vice President of Regulatory  
MaxCyte, Inc.

**Klaus Rose, MD, MS**  
CEO  
klausrose Consulting, Pediatric Drug Development  
& More

**Margaret A. Hamburg, MD**  
Former FDA Commissioner

**Michael Craig**  
Principal Consultant (CMC)  
Parexel Consulting

**Michael J. Vivion, PhD**  
Principal  
ECG Healthcare

**Mya Thomae**  
Regulatory Advisor

**Naseem F. Kabir**  
Director, Global Labeling  
Amgen Ltd.

**Neal E. Storm, DRSc, MBA, RAC**  
Director, Global Regulatory Affairs  
Amgen Inc.

**Pallavi Trevedi, MPH, RAC**  
Senior Associate  
Jeff Yuen and Associates, Inc.

**Sharry Arora**  
Manager

**Stephen Antonelli, PhD**  
Director, Regulatory CMC  
Alkermes, Inc.

**Suraj Ramachandran, RAC**  
Director Global Regulatory Affairs & Clinical Safety  
Devices and Digital Health  
Merck & Company

**Susan Capps**  
Executive Director, Global Value Access & Policy  
Amgen Ltd.

**Timothy Pang**  
Senior Director, Informa Pharma Consulting  
Informa Intelligence

**Tina Soulis, PhD**  
CEO  
Neuroscience Trials Australia

**Xinzhao Grace Jiang**  
Director  
Amgen, Inc.